-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HCW Biologics (NASDAQ:HCWB) Now Covered by Analysts at Jonestrading
HCW Biologics (NASDAQ:HCWB) Now Covered by Analysts at Jonestrading
Jonestrading initiated coverage on shares of HCW Biologics (NASDAQ:HCWB – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
HCW Biologics Trading Down 3.0 %
Shares of HCW Biologics stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 30.24 and a current ratio of 12.52. HCW Biologics has a 12-month low of $1.76 and a 12-month high of $3.32. The firm's 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.28.
Get HCW Biologics alerts:HCW Biologics (NASDAQ:HCWB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.45 million for the quarter.
Insiders Place Their Bets
In other news, CFO Rebecca Byam bought 50,000 shares of HCW Biologics stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the acquisition, the chief financial officer now owns 205,452 shares in the company, valued at $513,630. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have purchased 104,000 shares of company stock worth $265,230. Corporate insiders own 44.00% of the company's stock.Institutional Investors Weigh In On HCW Biologics
An institutional investor recently raised its position in HCW Biologics stock. HighTower Advisors LLC raised its stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) by 2,056.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,598 shares of the company's stock after acquiring an additional 205,598 shares during the quarter. HighTower Advisors LLC owned approximately 0.60% of HCW Biologics worth $588,000 at the end of the most recent quarter. 1.59% of the stock is owned by institutional investors and hedge funds.
About HCW Biologics
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Jonestrading initiated coverage on shares of HCW Biologics (NASDAQ:HCWB – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
據The Fly報道,瓊斯交易公司在週一發佈的一份研究報告中首次對卡夫生物(納斯達克代碼:HCWB-GET Rating)的股票進行了報道。該經紀公司對該股發佈了買入評級和8.00美元的目標價。
HCW Biologics Trading Down 3.0 %
HCW生物製品降價3.0%
Shares of HCW Biologics stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 30.24 and a current ratio of 12.52. HCW Biologics has a 12-month low of $1.76 and a 12-month high of $3.32. The firm's 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.28.
週一,HCW Biologics的股票開盤報2.25美元。該公司的負債權益比率為0.15,速動比率為30.24,流動比率為12.52。HCW Biologics的12個月低點為1.76美元,12個月高位為3.32美元。該公司的50日簡單移動均線切入位為2.33美元,200日簡單移動均線切入位為2.28美元。
HCW Biologics (NASDAQ:HCWB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.45 million for the quarter.
新華生物(納斯達克代碼:HCWB-GET Rating)最近一次發佈財報是在8月12日(星期五)。該公司公佈了該季度每股收益(0.10美元)。該公司本季度的收入為45萬美元。
Insiders Place Their Bets
內部人士下注
Institutional Investors Weigh In On HCW Biologics
機構投資者看好HCW生物製品
An institutional investor recently raised its position in HCW Biologics stock. HighTower Advisors LLC raised its stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) by 2,056.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,598 shares of the company's stock after acquiring an additional 205,598 shares during the quarter. HighTower Advisors LLC owned approximately 0.60% of HCW Biologics worth $588,000 at the end of the most recent quarter. 1.59% of the stock is owned by institutional investors and hedge funds.
一家機構投資者最近提高了對HCW Biologics股票的頭寸。根據HighTower Advisors LLC最近提交給美國證券交易委員會(SEC)的文件,該公司在第一季度將其在納斯達克生物公司(HKW Biologics Inc.)的股份增加了2,056.0%。該基金在本季度增持了205,598股後,持有215,598股該公司股票。截至最近一個季度末,HighTower Advisors LLC擁有HCW Biologics約0.60%的股份,價值58.8萬美元。1.59%的股票由機構投資者和對衝基金持有。
About HCW Biologics
關於HCW生物製品公司
(Get Rating)
(獲取評級)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
HCW生物製藥公司是一家臨牀前階段的生物製藥公司,專注於發現和開發針對慢性、低級別炎症和年齡相關疾病的新型免疫療法。該公司的主導產品包括HCW9218,這是一種可注射免疫療法,用於治療胰腺癌、卵巢癌、乳腺癌、前列腺癌和結直腸癌以及肺纖維化患者;以及HCW9302,用於治療自身免疫性疾病,如斑禿和代謝性疾病。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免費獲取StockNews.com關於HCW生物製品的研究報告(HCWB)
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎?
- 六面旗幟是一種你不想被困住的旅程
- 願景氫,現在的願景能源,將希望寄託在股票拆分上
- Hanesbrand可能發出零售類股本週表現不佳的信號
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《HCW生物製品日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對HCW Biologics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧